Suppr超能文献

术前口服碳水化合物对行冠状动脉旁路移植术的糖尿病患者胰岛素抵抗及术后恢复的影响:一项前瞻性、单盲、随机对照试验的研究方案。

Effects of pre-operative oral carbohydrates on insulin resistance and postoperative recovery in diabetic patients undergoing coronary artery bypass grafting: study protocol for a prospective, single-blind, randomized controlled trial.

机构信息

Department of Adult Cardiac Surgery, Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College/National Center for Cardiovasular Diseases, Beijing, China.

Department of Anesthesiology, Fuwai Yunnan Cardiovascular Hospital, Kunming, Yunnan Province, China.

出版信息

Trials. 2022 Dec 30;23(1):1067. doi: 10.1186/s13063-022-07042-w.

Abstract

BACKGROUND

Preoperative carbohydrates (CHO) supplement has been widely investigated in nondiabetic patients undergoing a variety of surgeries. It has been proved that preoperative CHO could alleviate postoperative insulin resistance (IR) and improve patients' well-being in nondiabetic patients. However, it remains controversial whether preoperative CHO could yield similar effects in diabetic patients. Till now, seldom has the administration of preoperative CHO been investigated in diabetic patients and there are limited studies reporting IR and postoperative recovery of diabetic patients undergoing cardiac surgery.

METHODS AND ANALYSIS

We present a prospective, single-center, single-blind, randomized, no-treatment controlled trial of preoperative CHO on diabetic patients undergoing off-pump coronary artery bypass grafting (OPCAB). A total of 62 patients will be enrolled and randomized to either Group CHO or Group control (CTRL). Patients in Group CHO will consume CHO fluid containing 50 g carbohydrates orally the evening before surgery (20:00-24:00) while their counterparts in Group CTRL will be fasted after 20:00 the evening before surgery. The primary endpoint is postoperative IR assessed via homeostasis model assessment (HOMA). The secondary endpoints are postoperative levels of potential mediators relating to IR including inflammatory factors and stress reaction characterized by serum cortisol. Exploratory endpoints are in-hospital clinical endpoints. Continuous variables will be compared by Student's t-test or Mann-Whitney U test. Categorical variables will be compared with χ test or Fisher's exact test. All tests in the present study are two-tailed and P<0.05 is considered statistically significant. All analyses will be performed with R 4.0.4.

DISCUSSION

This is the first prospective randomized controlled trial of preoperative CHO in diabetic patients undergoing cardiac surgery, with the hypothesis that preoperative CHO could improve postoperative IR and promote postoperative recovery. The research may assist in improving the clinical outcomes of diabetic patients undergoing OPCAB.

TRIAL REGISTRATION

The trial has been prospectively registered with ClinicalTrials.gov ( https://register.

CLINICALTRIALS

gov ) and Chinese Clinical Trial Registry ( http://www.chictr.org.cn ). Registry number is NCT05540249 and ChiCTR2000029664 respectively. Registered on Sept. 14, 2022.

CLINICAL TRIALS UNIT

Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

摘要

背景

术前碳水化合物(CHO)补充已在接受各种手术的非糖尿病患者中广泛研究。已证明术前 CHO 可减轻术后胰岛素抵抗(IR)并改善非糖尿病患者的舒适度。然而,术前 CHO 是否能在糖尿病患者中产生类似的效果仍存在争议。到目前为止,很少有研究调查糖尿病患者术前给予 CHO,也很少有研究报告行非体外循环冠状动脉旁路移植术(OPCAB)的糖尿病患者的 IR 和术后恢复情况。

方法和分析

我们提出了一项前瞻性、单中心、单盲、随机、无治疗对照试验,研究术前 CHO 对行 OPCAB 的糖尿病患者的影响。将纳入 62 例患者,并随机分为 CHO 组或对照组(CTRL)。CHO 组患者将于手术前一晚(20:00-24:00)口服含 50g 碳水化合物的 CHO 液,而 CTRL 组患者则于手术前一晚 20:00 后禁食。主要终点是通过稳态模型评估(HOMA)评估术后 IR。次要终点是与 IR 相关的潜在介质(包括炎症因子和血清皮质醇特征的应激反应)的术后水平。探索性终点是住院临床终点。连续变量采用 Student's t 检验或 Mann-Whitney U 检验进行比较。分类变量采用 χ 检验或 Fisher 确切检验进行比较。本研究中的所有检验均为双侧检验,P<0.05 为统计学显著。所有分析均使用 R 4.0.4 进行。

讨论

这是首个研究术前 CHO 在心脏手术的糖尿病患者中的前瞻性随机对照试验,假设术前 CHO 可改善术后 IR 并促进术后恢复。该研究可能有助于改善行 OPCAB 的糖尿病患者的临床结局。

试验注册

该试验已前瞻性地在 ClinicalTrials.gov(https://register. clinicaltrials.gov)和中国临床试验注册中心(http://www.chictr.org.cn)注册。注册号分别为 NCT05540249 和 ChiCTR2000029664,于 2022 年 9 月 14 日注册。

临床试验单位

中国医学科学院北京协和医学院国家心血管病中心阜外医院,北京,中国。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f869/9801544/d7e7a0546cc8/13063_2022_7042_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验